Veraxa Biotech is trading 10.19% up at $1.19 on October 7, 2026, after announcing the implementation of FDA-aligned New Approach Methodologies across its preclinical programs. - These methodologies, including cell-based assays and computational models, aim to reduce animal testing and accelerate development time. - The announcement is seen as a company-specific catalyst, driving the stock up against a backdrop of a falling biotech sector and broader U.S. indexes.